Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
60 hedge funds and large institutions have $54.8M invested in Cidara Therapeutics in 2018 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 8 closing their positions.
5,680% more call options, than puts
Call options by funds: $867K | Put options by funds: $15K
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
25% more funds holding
Funds holding: 48 → 60 (+12)
0.39% less ownership
Funds ownership: 3.69% → 3.3% (-0.39%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
46% less capital invested
Capital invested by funds: $102M → $54.8M (-$46.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.43M |
| 2 |
BlackRock
New York
|
+$1.24M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$826K |
| 4 |
Goldman Sachs
New York
|
+$698K |
| 5 |
Renaissance Technologies
New York
|
+$563K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.44M |
| 2 |
BC
Broadfin Capital
New York
|
-$3.29M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$3.15M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$1.87M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.32M |
CDTX Hedge Fund Activity: Q1 2018 in Review
60 of the 4,372 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2018, worth a combined $54.8M — down 46% from $102M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CDTX positions and 8 closed out — a net gain of 12 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $2.43M. The largest seller was Great Point Partners, exiting entirely with an estimated $5.44M sold.
- 60 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2018, up from 48 in Q4 2017.
- Funds reported $54.8M of Cidara Therapeutics stock for Q1 2018, down 46% quarter-over-quarter.
- 20 funds opened new Cidara Therapeutics positions in Q1 2018 and 8 closed out, a net change of +12 holders.
- The largest Cidara Therapeutics buyer in Q1 2018 was Adage Capital Partners, an estimated $2.43M added.
- The largest Cidara Therapeutics seller in Q1 2018 was Great Point Partners, an estimated $5.44M sold.
Based on aggregated 13F filings for Q1 2018.